Simulations Plus, Inc. has announced a technical collaboration with NVIDIA to develop GPU-accelerated, AI-assisted modeling workflows for drug development. The initiative combines Simulations Plus’ physiologically-based pharmacokinetics (PBPK), pharmacokinetics/pharmacodynamics (PK/PD), and quantitative systems pharmacology (QSP) modeling capabilities with NVIDIA’s accelerated computing, AI technologies, and the BioNeMo platform. The collaboration aims to support simulation scaling, parameter exploration, and virtual population studies.
Initial areas of focus include:
- GPU-optimized scientific engines for QSP and PK/PD modeling
- AI-assisted workflows for model construction, diagnostics, and refinement
- Expanded QSP capabilities, with testing indicating a significant reduction in end-to-end modeling time
Image generated by: ChatGPT
